abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Author

Rheumatol Ther. 2020 Sep;7(3):553-580.doi: 10.1007/s40744-020-00209-4. Epub 2020 Jun 6.

Peter Nash 1Laura C Coates 2Alan J Kivitz 3Philip J Mease 4Dafna D Gladman 5José A Covarrubias-Cobos 6Oliver FitzGerald 7Dona Fleishaker 8Cunshan Wang 8Joseph Wu 8Ming-Ann Hsu 8Sujatha Menon 8Lara Fallon 9Ana Belén Romero 10Keith S Kanik 8

Author Information

1 School of Medicine, Griffith University, Brisbane, QLD, Australia.

2 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

3 Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, USA.

4 Swedish Medical Center/Providence St Joseph Health and University of Washington, Seattle, WA, USA.

5 Department of Medicine, University of Toronto and Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada.

6 Unidad Rheumatologica Las Americas S.C.P, Mérida, Mexico.

7 Conway Institute for Biomolecular Research, School of Medicine, University College Dublin, Dublin, Ireland.

8 Pfizer Inc, Groton, CT, USA.

9 Pfizer Inc, Montreal, QC, Canada. lara.fallon@pfizer.com.

10 Pfizer Inc, Barcelona, Spain.

Abstract

Introduction: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; database not locked, data may change).

Methods: Eligible patients from two phase (P) 3 (P3) tofacitinib PsA studies (OPAL Broaden, NCT01877668; OPAL Beyond, NCT01882439) entered OPAL Balance ≤ 3 months after completing the P3 study or discontinuing for reasons other than study-drug-related adverse events (AEs). Patients received open-label tofacitinib 5 mg twice daily (BID), with adjustments to 10 mg BID permitted post-month (M) 1. Certain concomitant conventional synthetic disease-modifying antirheumatic drugs were allowed. Primary endpoints were incidence/severity of AEs and laboratory abnormalities, and changes from baseline in laboratory parameters (reported up to M36 and M30, respectively). Efficacy (clinical/patient-reported outcomes) was reported through M30.

Results: A total of 686 patients were treated; at data cut-off, 68.2% remained in the study. Mean (range) treatment duration was 641 (1-1032) days; total treatment duration was 1153.2 patient-years. By M36, 79.6, 13.8, and 8.6% of patients reported AEs, serious AEs, and discontinuations due to AEs, respectively. Five deaths occurred; one within the risk period (incidence rate [IR; patients with events/100 patient-years] 0.1). IRs for AEs of special interest were: all (non-serious and serious) herpes zoster, 1.7; serious infections, 0.9; opportunistic infections, 0.3 (all disseminated/multi-dermatomal herpes zoster); malignancies excluding non-melanoma skin cancer (NMSC), 0.8; NMSC, 1.0; major adverse cardiovascular events, 0.3; pulmonary embolisms, 0.1; and arterial thromboembolisms, 0.4. No patients had deep vein thrombosis. Alanine aminotransferase and aspartate aminotransferase levels were elevated ≥ 3-fold the upper limit of normal in 4.0 and 2.2% of patients, respectively. Changes in laboratory parameters were generally stable over time, although lymphocyte counts decreased slightly. Efficacy was maintained through M30.

Conclusions: In this interim analysis of OPAL Balance, tofacitinib safety and efficacy in patients with PsA appeared to be consistent with those of the P3 studies. Efficacy was maintained over time.

 

Trial registration: ClinicalTrials.gov identifier: NCT01976364.